More News of Interest

PROCEPT BioRobotics Announces Three-Year Follow-Up Data Confirming Sustained Efficacy, Superior Safety of Aquablation® Therapy for Benign Prostatic Hyperplasia

Reza Zadno, president and CEO of PROCEPT BioRobotics notes, “The publication of these three-year study results is a very important milestone for PROCEPT BioRobotics, as it provides compelling evidence of the long-term durability and safety of Aquablation therapy.”  He added, “We are thrilled to see the results and agree with the study co-authors, who concluded that autonomous robotic technology may ultimately offer standardization that improves overall outcomes for all urologists and their patients.”

The AquaBeam Robotic System is the first FDA-granted surgical robot for the autonomous removal of prostate tissue in males suffering from benign prostatic hyperplasia. In the study, 181 patients with prostates sized 30 to 80 cc were randomized to either Aquablation therapy or TURP. At three years, investigators found that improvements in IPSS scores, Qmax, PVR, and PSA were statistically similar across groups, but noted superior symptom improvement in the Aquablation therapy arm for patients with prostates larger than 50cc. Moreover, changes in MSHQ-EjD and MSHQ bother scores were significantly lower in the Aquablation therapy group. Additionally, no patients required surgical retreatments for BPH beyond 20 months.

“The high-quality results of this three-year study build on a large foundation of clinical data supporting the safety and efficacy of Aquablation therapy for the treatment of BPH,” said Study Co-author Peter Gilling, M.D, Professor of Surgery at the University of Auckland, Bay of Plenty Clinical School Tauranga. “Unlike any other BPH treatment currently available, Aquablation therapy integrates image guidance and robotic execution, and I believe that Aquablation has the potential to become a new standard of care for urologists and their patients.”

Latest Posts

Don't Miss